Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

01 sept. 2016 08h00 HE | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc. To Present at Two Upcoming Investor Conferences

BOSTON, Sept. 01, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced that the company will participate in two upcoming investor conferences. Paratek is a...
15 août 2016 08h00 HE | Source: Paratek Pharmaceuticals

Paratek Initiates Phase 3 Study of Oral-only Omadacycline in ABSSSI

BOSTON, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today the dosing of the first patient in its second pivotal Phase 3 study of omadacycline in...
04 août 2016 07h00 HE | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc. Reports Second Quarter 2016 Financial and Operating Results

Reported positive Phase 3 study results with omadacycline in acute bacterial skin and skin structure infections Accelerated timing to report top-line data of the omadacycline Phase 1b urinary...
22 juil. 2016 10h57 HE | Source: Paratek Pharmaceuticals

Paratek Pharmaceuticals to Report Second Quarter 2016 Financial Results on August 4, 2016

BOSTON, July 22, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
27 juin 2016 12h02 HE | Source: Paratek Pharmaceuticals

Paratek Announces Closing of Common Stock Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

BOSTON, June 27, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
22 juin 2016 08h00 HE | Source: Paratek Pharmaceuticals

Paratek Announces Pricing of Public Offering of 4,250,000 Shares of Common Stock

BOSTON, June 22, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
20 juin 2016 16h01 HE | Source: Paratek Pharmaceuticals

Paratek Announces Proposed Public Offering of Common Stock

BOSTON, June 20, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
20 juin 2016 08h00 HE | Source: Paratek Pharmaceuticals

Paratek Accelerates Timing for Projected Reporting of Top-Line Data for Omadacycline Phase 1b Urinary Tract Infection Study

BOSTON, June 20, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that it projects its ongoing phase 1b clinical study evaluating omadacycline in the treatment...
16 juin 2016 16h05 HE | Source: Paratek Pharmaceuticals

Paratek Announces that Omadacycline Met All Primary and Secondary Efficacy Outcomes Designated by FDA and EMA in a Phase 3 Study in Acute Bacterial Skin Infections; Omadacycline was Generally Safe and Well-Tolerated

Company to host a webcast and conference call for investors at 4:30 pm EDT to review top-line results BOSTON, June 16, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK)...
13 juin 2016 16h01 HE | Source: Paratek Pharmaceuticals

Paratek to Present Omadacycline Microbiologic, Pharmacokinetic and Clinical Data at ASM Microbe 2016

- Biofilm, post-antibiotic effects, microbiologic surveillance and omadacycline in vitro activity against select pathogens to be presented - Clinical PK and Modelling Strategies for omadacycline to...

Page précédente